ARTICLE | Company News
Ilex cancer licensing deal with BASF
September 6, 2000 7:00 AM UTC
ILXO received exclusive worldwide rights to BASF's BSF223651 tubulin interactive, anti-mitotic synthetic pentapeptide analog of dolastatin. The compound is in preclinical testing. ILXO also will recei...